Document Detail

Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan.
MedLine Citation:
PMID:  23030295     Owner:  NLM     Status:  MEDLINE    
Angiotensin II receptor blockers (ARBs) inhibit the renin-angiotensin system. As a result, these agents provide beneficial effects in terms of cardiovascular (CV) and renal protection, independent of their blood pressure-lowering effects. Telmisartan and valsartan are the most intensively studied ARBs for the effects on CV outcomes. Randomized clinical trials assessing morbidity and mortality end points have included a range of patient types, including those with hypertension, hypertension with Type 2 diabetes, high CV risk without hypertension, ischemic heart disease, stroke and heart failure. Few head-to-head comparisons between telmisartan and valsartan have been performed. However, some blood pressure-independent properties of these two ARBs can be scrutinized from separate studies in the available literature.
Massimo Volpe
Related Documents :
11514285 - Am reverses pressor response to et-1 independently of no in rat coronary circulation.
10383495 - Hypoxia and hyperoxia both transiently affect distribution of pulmonary perfusion but n...
9267635 - Measurement of vasoactivity in the guinea-pig choroid.
7468245 - Effect of calcium ions on resting oxygen consumption of the myocardium.
10788965 - A comparison of carbon dioxide monitoring and oxygenation between facemask and divided ...
9743175 - The physiologic effects of inverse ratio ventilation.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  10     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-10-03     Completed Date:  2013-02-27     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1061-72     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II Type 2 Receptor Blockers / adverse effects,  therapeutic use*
Antihypertensive Agents / adverse effects,  therapeutic use*
Benzimidazoles / adverse effects,  therapeutic use*
Benzoates / adverse effects,  therapeutic use*
Cardiovascular Diseases / complications,  etiology,  prevention & control*
Diabetes Mellitus, Type 2 / complications,  physiopathology
Evidence-Based Medicine
Hypertension / complications,  drug therapy,  physiopathology
Tetrazoles / adverse effects,  therapeutic use*
Valine / adverse effects,  analogs & derivatives*,  therapeutic use
Reg. No./Substance:
0/Angiotensin II Type 2 Receptor Blockers; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Benzoates; 0/Tetrazoles; 137862-53-4/valsartan; HG18B9YRS7/Valine; U5SYW473RQ/telmisartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Coronary heart disease in Type 2 diabetes: mechanisms and comprehensive prevention strategies.
Next Document:  Expression of NOX5 in human teratozoospermia compared to normozoospermia.